Shahzad N. Raza
Expertise in
61
conditions

Dr. Shahzad N. Raza

Hematology Oncology | Hematology | Oncology
10201 Carnegie Avenue, 
Cleveland, OH 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Referral may be required
Before you request
Expertise in
61
conditions
10201 Carnegie Avenue, 
Cleveland, OH 

Overview

Shahzad Raza is a Hematologist Oncology specialist and a Hematologist practicing medicine in Cleveland, Ohio.

Dr. Raza is highly rated in 61 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Primary Amyloidosis, Relapsed Refractory Multiple Myeloma (RRMM), Bone Marrow Aspiration, and Tissue Biopsy.

Dr. Raza is board certified in American Board Of Internal Medicine, 2015. He is actively involved in clinical research, co-authoring 143 peer reviewed articles and participating in 7 clinical trials. Dr. Raza is currently accepting new patients.

Specialties

Hematology Oncology
Hematology
Oncology

Licenses

Internal Medicine in MO

Board Certifications

American Board Of Internal Medicine, 2015

Fellowships

University of Missouri Hospitals & Clinics

Hospital Affiliations

Hillcrest Hospital
Cleveland Clinic
Mercy Medical Center
Akron General Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Ambetter
  • EPO
  • HMO
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
AultCare
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
CommuniCare Advantage
  • MEDICARE SNP
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
First Health
  • INSURANCE PLAN
  • MEDICARE PDP
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medical Mutual
  • HMO
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
Paramount
  • EPO
  • HMO
  • INDEMNITY
  • PPO
Primetime Health Plan
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE PART D
Provider Partners Health Plan
  • MEDICARE SNP
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
SummaCare
  • HMO
  • PPO
TeamCare
  • OTHER COMMERCIAL
The Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Univera Healthcare
  • INSURANCE PLAN
  • MEDICARE MAPD
UPMC
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 23 Less Insurance Carriers -

Locations

Cleveland Clinic Main Campus
10201 Carnegie Avenue, Cleveland, OH 44106

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)
Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)
Enrollment Status: Recruiting
Publish Date: August 19, 2026
Intervention Type: Other, Biological, Drug
Study Drugs: Daratumumab, Dexamethasone, Lenalidomide
Study Phase: Phase 3
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2026
Intervention Type: Other, Drug
Study Drugs: Temozolomide, Veliparib
Study Phase: Phase 2/Phase 3
A Multicenter, Open-Label Study With a Randomized Control Arm of the Efficacy, Safety, and Pharmacokinetics of Intravenously Infused Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme After Failure of Standard First Line Therapy
A Multicenter, Open-Label Study With a Randomized Control Arm of the Efficacy, Safety, and Pharmacokinetics of Intravenously Infused Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme After Failure of Standard First Line Therapy
Enrollment Status: Active_not_recruiting
Publish Date: April 15, 2026
Intervention Type: Drug
Study Drugs: Berubicin, Lomustine
Study Phase: Phase 2
Phase 3 Randomized Trial of DFP-10917 vs Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine, Venetoclax Combination Regimens) or Intensive Reinduction (High & Intermediate Dose Cytarabine Regimens) for Acute Myelogenous Leukemia Patients in Second, Third, or Fourth Salvage
Phase 3 Randomized Trial of DFP-10917 vs Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine, Venetoclax Combination Regimens) or Intensive Reinduction (High & Intermediate Dose Cytarabine Regimens) for Acute Myelogenous Leukemia Patients in Second, Third, or Fourth Salvage
Enrollment Status: Terminated
Publish Date: January 22, 2026
Intervention Type: Drug
Study Drugs: DFP-10917, Cytarabine, Azacitidine, Decitabine, Mitoxantrone, Etoposide, Fludarabine, Idarubicin, Venetoclax, Cladribine
Study Phase: Phase 3
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Enrollment Status: Active_not_recruiting
Publish Date: December 19, 2025
Intervention Type: Other, Drug
Study Drug: Crizotinib
Study Phase: Phase 3
A Phase 2, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects With Relapsed or Refractory Marginal Zone Lymphoma With or Without Prior Exposure to a BTK Inhibitor (CITADEL-204)
A Phase 2, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects With Relapsed or Refractory Marginal Zone Lymphoma With or Without Prior Exposure to a BTK Inhibitor (CITADEL-204)
Enrollment Status: Completed
Publish Date: July 11, 2025
Intervention Type: Drug
Study Drug: Parsaclisib
Study Phase: Phase 2
A Phase 2 Trial for Patients With Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide, and BMX-001
A Phase 2 Trial for Patients With Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide, and BMX-001
Enrollment Status: Completed
Publish Date: June 08, 2025
Intervention Type: Drug, Radiation
Study Drugs: BMX-001, Temozolomide
Study Phase: Phase 1/Phase 2
View 6 Less Clinical Trials

143 Total Publications

Limited duration of dexamethasone in newly diagnosed AL amyloidosis: impact on response, toxicity, and survival.
Limited duration of dexamethasone in newly diagnosed AL amyloidosis: impact on response, toxicity, and survival.
Journal: Annals of medicine
Published: August 07, 2026
Similar Doctors
Expertise in
30
conditions
Dr. Brian T. Hill
Hematology Oncology | Hematology | Oncology
Expertise in
30
conditions
Dr. Brian T. Hill
Hematology Oncology | Hematology | Oncology
Referral may be required
Before you request

Cleveland Clinic Main Campus

9500 Euclid Avenue, 
Cleveland, OH 
 (0.3 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Brian Hill is a Hematologist Oncology specialist and a Hematologist practicing medicine in Cleveland, Ohio. Dr. Hill is highly rated in 30 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Hill is currently accepting new patients.

Expertise in
37
conditions
Dr. Paolo F. Caimi
Hematology Oncology | Hematology | Oncology
Expertise in
37
conditions
Dr. Paolo F. Caimi
Hematology Oncology | Hematology | Oncology
Referral may be required
Before you request

Cleveland Clinic Main Campus

9500 Euclid Avenue, 
Cleveland, OH 
 (0.3 miles away)
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Paolo Caimi is a Hematologist Oncology specialist and a Hematologist practicing medicine in Cleveland, Ohio. Dr. Caimi is highly rated in 37 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), B-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Caimi is board certified in American Board Of Internal Medicine, 2011. Dr. Caimi is currently accepting new patients.

Expertise in
24
conditions
Dr. Aaron T. Gerds
Hematology Oncology | Hematology | Oncology
Expertise in
24
conditions
Dr. Aaron T. Gerds
Hematology Oncology | Hematology | Oncology
Referral may be required
Before you request

Cleveland Clinic Main Campus

9500 Euclid Avenue, 
Cleveland, OH 
 (0.3 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Aaron Gerds is a Hematologist Oncology specialist and a Hematologist practicing medicine in Cleveland, Ohio. Dr. Gerds is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Myelofibrosis, Myeloproliferative Neoplasms (MPN), Polycythemia Vera, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Gerds is board certified in American Board Of Internal Medicine, 2013. Dr. Gerds is currently accepting new patients.

Frequently Asked Questions about Dr. Shahzad N. Raza

How do I make an appointment with Dr. Shahzad N. Raza?

You can book an appointment with Dr. Shahzad N. Raza by calling their office at 866-223-8100. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Shahzad N. Raza a top-rated expert for Multiple Myeloma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Shahzad N. Raza is classified as an Elite expert for Multiple Myeloma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Shahzad N. Raza specialize in?

While Dr. Shahzad N. Raza is a Hematology Oncology, they have specific expertise in Multiple Myeloma, Primary Amyloidosis, and Relapsed Refractory Multiple Myeloma (RRMM). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology Oncology.

Does Dr. Shahzad N. Raza participate in research or clinical trials?

Yes. Dr. Shahzad N. Raza has published 143 articles and abstracts on conditions like Multiple Myeloma. You can view a list of Dr. Shahzad N. Raza's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Shahzad N. Raza accept my insurance?

Dr. Shahzad N. Raza accepts most major insurance plans, including Aetna and Ambetter. We recommend calling the office directly at 866-223-8100 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Raza's expertise for a condition
ConditionClose
View All 13 Distinguished Conditions
View All 46 Advanced Conditions
View All 115 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile